secwatch.observer — SEC 8-K summary
======================================

Issuer:     JOHNSON & JOHNSON (JNJ)
CIK:        0000200406
Form:       8-K
Filed at:   2024-01-23T23:59:59+00:00
Accession:  0000200406-24-000004
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

JNJ Q4 2023 revenue $21.4B (+7.3% YoY), adjusted EPS $2.29 (+11.7%)
-------------------------------------------------------------------

- Q4 sales $21,395M (+7.3% YoY); FY 2023 sales $85,159M (+6.5% YoY).
- Q4 net earnings from continuing ops $4,132M (diluted EPS $1.70, +39.3% YoY).
- Adjusted Q4 net earnings from continuing ops $5,562M (diluted EPS $2.29, +11.7% YoY).
- Innovative Medicine ex-COVID vaccine grew 9.7% in Q4; MedTech grew 13.3%.
- FY 2023 operational sales growth 7.4% total, 8.0% ex-COVID vaccine.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/200406/000020040624000004/0000200406-24-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/200406/000020040624000004/jnj-20240123.htm
  HTML page:      https://secwatch.observer/filing/0000200406-24-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer